Hepatitis C and injecting drug use: impact, costs and policy options
Hepatitis C infections occurring in recent years in the European Union may cost countries billions of euros in future healthcare, according to research published in this monograph. A conglomeration of state-of-the-art research on hepatitis C, drug use and public health methods, this publication pres...
| Beteiligte: | |
|---|---|
| Medienart: | Elektronisch Buch |
| Sprache: | Englisch |
| Veröffentlicht: |
Luxemburg
Office for Official Publications of the European Communities
2004
|
| In: |
EMCDDA scientific monograph series (7)
Jahr: 2004 |
| Online Zugang: |
Volltext (kostenfrei) Volltext (kostenfrei) Volltext (kostenfrei) |
| Verfügbarkeit prüfen: | HBZ Gateway |
| Schlagwörter: | |
| Ähnliche Datensätze: | Erscheint auch als:
471720607 |
| Zusammenfassung: | Hepatitis C infections occurring in recent years in the European Union may cost countries billions of euros in future healthcare, according to research published in this monograph. A conglomeration of state-of-the-art research on hepatitis C, drug use and public health methods, this publication presents analyses on the impact and costs of the disease among injecting drug users, as a basis for sound policy-making. Other issues addressed include: quality of life; treatment, surveillance and prevention; and the cost-effectiveness of measures such as needle-exchange programmes and substitution therapy. Hepatitis C affects an estimated 170 million people worldwide and at least a million, but possibly several million, people in Western Europe who are at risk of developing liver cirrhosis or liver cancer. It is a highly infectious and potentially fatal blood-borne disease that attacks the liver and for which there is as yet no vaccine. |
|---|---|
| Beschreibung: | 1 Online-Ressource (391 Seiten) |
| DOI: | 10.15496/publikation-23211 |